Efficacy and Safety Of Xeloda as Sequential Adjuvant Therapy After Chemotherapy in Breast Cancer
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
Select 600 cases of women with breast cancer of triple negative or Her-2 positive or with
more than 4 axillary lymph node metastasis. All the patients were accepted the chemotherapy
of Anthracycline and/or Taxane. Divide them into two groups randomly. Then the experimental
group will be treated with Xeloda(1000mg/m2,orally,2 times/day) for six cycles (21
days/cycle,each taking two weeks suspending for one week) as Sequential Adjuvant Therapy. And
the control group will not receive any adjuvant therapy.Finally the investigators will assess
the 5-year disease-free survival, 5 years and 10-year overall survival and safety of using
medications.